Ranee Mehra

16.1k total citations · 4 hit papers
194 papers, 6.5k citations indexed

About

Ranee Mehra is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Ranee Mehra has authored 194 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 102 papers in Pulmonary and Respiratory Medicine and 86 papers in Otorhinolaryngology. Recurrent topics in Ranee Mehra's work include Head and Neck Cancer Studies (86 papers), Lung Cancer Treatments and Mutations (81 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Ranee Mehra is often cited by papers focused on Head and Neck Cancer Studies (86 papers), Lung Cancer Treatments and Mutations (81 papers) and Cancer Immunotherapy and Biomarkers (45 papers). Ranee Mehra collaborates with scholars based in United States, South Korea and Italy. Ranee Mehra's co-authors include Barbara Burtness, Laura Q.M. Chow, Tanguy Y. Seiwert, Jonathan D. Cheng, Joseph P. Eder, Jared Weiss, John A. Ridge, Raanan Berger, Karl Heath and Jared Lunceford and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ranee Mehra

187 papers receiving 6.4k citations

Hit Papers

Safety and clinical activ... 2011 2026 2016 2021 2016 2011 2018 2015 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
    2016 1.3k citations Tanguy Y. Seiwert, Barbara Burtness et al. profile →
  2. Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
    2011 445 citations Arlene A. Forastiere, Roger B. Cohen et al. Journal of Clinical Oncology profile →
  3. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
    2018 329 citations Ranee Mehra, Tanguy Y. Seiwert et al. profile →
  4. Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States
    2015 298 citations Thomas J. Galloway, Ranee Mehra et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ranee Mehra 4.1k 2.3k 1.7k 1.5k 1.4k 194 6.5k
Renata Ferrarotto 2.7k 0.7× 975 0.4× 694 0.4× 933 0.6× 1.6k 1.1× 210 4.7k
Federica Perrone 3.6k 0.9× 2.7k 1.2× 1.0k 0.6× 2.1k 1.5× 2.0k 1.5× 235 7.9k
Scott A. Laurie 4.3k 1.1× 3.3k 1.4× 724 0.4× 1.2k 0.8× 1.2k 0.9× 163 6.3k
Lori J. Wirth 4.3k 1.1× 2.4k 1.0× 1.4k 0.8× 2.0k 1.3× 1.8k 1.3× 260 9.9k
Hyunseok Kang 2.0k 0.5× 889 0.4× 1.0k 0.6× 772 0.5× 1000 0.7× 102 3.4k
Frédéric Rolland 4.3k 1.1× 6.7k 2.9× 2.6k 1.5× 4.8k 3.2× 2.7k 2.0× 142 11.6k
Ihor Vynnychenko 4.6k 1.1× 4.3k 1.9× 1.4k 0.8× 1.4k 1.0× 1.4k 1.0× 57 7.0k
Erminia Massarelli 3.2k 0.8× 2.1k 0.9× 551 0.3× 1.2k 0.8× 510 0.4× 140 4.6k
Nadia Amellal 5.3k 1.3× 4.0k 1.8× 4.2k 2.5× 2.1k 1.4× 2.4k 1.7× 60 9.0k
Roger Ove 2.0k 0.5× 1.7k 0.8× 1.7k 1.0× 978 0.7× 1.1k 0.8× 36 4.1k

Countries citing papers authored by Ranee Mehra

Since Specialization
Citations

This map shows the geographic impact of Ranee Mehra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranee Mehra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranee Mehra more than expected).

Fields of papers citing papers by Ranee Mehra

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranee Mehra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranee Mehra. The network helps show where Ranee Mehra may publish in the future.

Co-authorship network of co-authors of Ranee Mehra

This figure shows the co-authorship network connecting the top 25 collaborators of Ranee Mehra. A scholar is included among the top collaborators of Ranee Mehra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranee Mehra. Ranee Mehra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhatia, Aarti, Ranee Mehra, Jessica R. Bauman, et al.. (2025). Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck. Head & Neck. 47(9). 2373–2382. 2 indexed citations
2.
Burtness, Barbara, Yael Flamand, Harry Quon, et al.. (2025). Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer. Journal of Clinical Oncology. 43(23). 2559–2565. 4 indexed citations
3.
Aggarwal, Charu, Daniel H. Sterman, Erin R. Alesi, et al.. (2024). Overall survival after treatment with CAN-2409 plus valacyclovir in combination with continued ICI in patients with stage III/IV NSCLC with an inadequate response to ICI.. Journal of Clinical Oncology. 42(16_suppl). 8634–8634. 6 indexed citations
4.
El-Khoueiry, Anthony B., Elena Garralda, Andrés Cervantes, et al.. (2024). A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). 2531–2531. 1 indexed citations
5.
6.
Rizvi, Naiyer A., Foluso O. Ademuyiwa, Z. Alexander Cao, et al.. (2023). Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy. Journal for ImmunoTherapy of Cancer. 11(3). e005920–e005920. 24 indexed citations
7.
Brown, Jessica, Rodney J. Taylor, Jeffrey S. Wolf, et al.. (2023). Regionalization of Head and Neck Oncology Tumor Boards: Perspectives of Collaborating Physicians. OTO Open. 7(1). e18–e18. 2 indexed citations
8.
Yong, Candice, et al.. (2022). Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. SHILAP Revista de lepidopterología. 7 indexed citations
9.
Haddad, Robert I., Tanguy Y. Seiwert, Laura Q.M. Chow, et al.. (2022). Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(2). e003026–e003026. 54 indexed citations
10.
Yang, Zejia, Jipei Liao, Lisa M. Schumaker, et al.. (2022). Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma. Oral Oncology. 131. 105939–105939. 8 indexed citations
11.
Amr, Sania, et al.. (2021). Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma. Head & Neck. 43(12). 3935–3945. 4 indexed citations
12.
McCusker, Michael G., Ranee Mehra, Sania Amr, et al.. (2021). Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment. Head & Neck. 44(3). 749–759. 3 indexed citations
13.
Weiss, Jared, Siddharth Sheth, Allison M. Deal, et al.. (2020). Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication. Clinical Cancer Research. 26(16). 4260–4267. 29 indexed citations
14.
Lee, Jong Woo, Teresa Sandoval-Schaefer, Kyung Jin Eoh, et al.. (2019). Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Research. 25(11). 3430–3442. 58 indexed citations
15.
Churilla, T.M., Ranee Mehra, Miriam N. Lango, et al.. (2016). Long-Term Toxicities in Survivors of Radiation Treatment for Head and Neck Cancer. International Journal of Radiation Oncology*Biology*Physics. 96(2). E394–E394.
16.
Egloff, Ann Marie, Ju-Whei Lee, Corey J. Langer, et al.. (2014). Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303. Clinical Cancer Research. 20(19). 5041–5051. 26 indexed citations
17.
Mehra, Ranee, Fang Zhu, Dong‐Hua Yang, et al.. (2013). Quantification of Excision Repair Cross-Complementing Group 1 and Survival in p16-Negative Squamous Cell Head and Neck Cancers. Clinical Cancer Research. 19(23). 6633–6643. 21 indexed citations
18.
Hayes, D. Neil, Tawee Tanvetyanon, Monika K. Krzyzanowska, et al.. (2012). Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements. Clinical Cancer Research. 18(7). 2056–2065. 120 indexed citations
19.
Tejani, Mohamedtaki Abdulaziz, Roger B. Cohen, & Ranee Mehra. (2010). The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancer. SHILAP Revista de lepidopterología. 8 indexed citations
20.
Mehra, Ranee & Barbara Burtness. (2006). Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion on Biological Therapy. 6(9). 951–962. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Renata Ferrarotto Breakdown of academic impact, for papers by Federica Perrone Breakdown of academic impact, for papers by Scott A. Laurie Breakdown of academic impact, for papers by Lori J. Wirth Breakdown of academic impact, for papers by Hyunseok Kang Breakdown of academic impact, for papers by Frédéric Rolland Breakdown of academic impact, for papers by Ihor Vynnychenko Breakdown of academic impact, for papers by Erminia Massarelli Breakdown of academic impact, for papers by Nadia Amellal Breakdown of academic impact, for papers by Roger Ove
Rankless by CCL
2026